Overview: Alcohol Biomarkers EtG EtS Panel
Introduction: The Alcohol Biomarkers EtG EtS Panel detects recent alcohol consumption using urine samples. In India, alcohol use disorder (AUD) affects millions, with prevalence ~14.6% among adult males (NFHS data), hazardous drinking in two-fifths of users, and dependence in 23% among drinkers. Consumption is higher in men (29.2% in NFHS-4, declining to ~22% in NFHS-5), with regional variations (high in NE/East/South states). Disorders present with behavioral changes, liver dysfunction, family/social issues, and severe complications like cirrhosis if untreated. High morbidity from underdiagnosis in rural/low-SES groups, stigma, limited rehab access. Per toxicology practices (aligned ICMR/NACO guidelines), test uses HPLC-MS/MS for parameter analysis over 1-2 days with high sensitivity/specificity, valuable for objective screening in addiction clinics, workplaces, legal cases. Targets suspected alcohol use/abuse, addressing accurate biomarker detection for treatment planning. With elevated morbidity/underdiagnosis (e.g., 20-30% healthcare costs linked to alcohol), supports public health efforts for early intervention, reduced complications, family impact. Urine-based approach ensures reliable detection in India's diverse settings.
Other Names: EtG EtS Pnl.
FDA Status: FDA approved, CLIA certified for toxicology, compliant with 2025 standards.
Historical Milestone: Introduced 2000s with EtG/EtS discovery; in India, gained use in addiction centers post-NFHS highlighting high dependence.
Purpose: Screens for 3 parameters including ethyl glucuronide to guide alcohol abuse assessment, detect recent consumption (up to days), inform treatment/prevention in high-prevalence areas.
Test Parameters: 1. Ethyl Glucuronide (EtG), 2. Ethyl Sulphate (EtS), 3. Ethanol.
Pretest Condition: No fasting; report recent alcohol intake or related symptoms.
Specimen: 10 mL urine in 1 sterile container, transported promptly.
Sample Stability at Room Temperature: 24 hours proper handling to preserve integrity.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, short-term storage preferred.
Sample Stability at Frozen: 6 months at -20 degrees Celsius, long-term storage.
Medical History: Details on alcohol patterns, behavioral changes, liver issues, family history of alcoholism.
Consent: Written consent detailing purpose, risks untreated (liver disease, family violence), benefits early detection, minimal discomfort.
Procedural Considerations: Processing using HPLC-MS/MS by trained personnel, sterile technique, avoid contamination, interpret 1-2 days with controls. Labs controlled, quality assurance, kit storage per specs.
Factors Affecting Result Accuracy: Delays, improper storage, dilution, recent heavy drinking affect results. Clinical correlation/additional testing recommended.
Clinical Significance: Abnormal indicates recent consumption, further investigation/specialist. Normal follow-up if history suggests use.
Specialist Consultation: GPs/addiction medicine specialists for management, treatment planning, coordination with programs.
Additional Supporting Tests: Blood alcohol, CDT, liver function tests confirmation.
Test Limitations: False negatives light/long-ago consumption, false positives incidental exposure; comprehensive approach required.
References: NFHS-5 Alcohol Data 2021, Indian Journal of Psychiatry 2024, Toxicology Guidelines 2023.
